CommercialDocumentationMedium impact
08.00.90v, Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound)/(Abraxane® for Injectable Suspension)
Independence Blue Cross·Oncology, Pharmacy·Pharmacy
Effective date
Jul 13, 2026
We identified it
Jul 14, 2026
Summary
Policy 08.00.90v for Abraxane (Paclitaxel Protein-Bound Particles) has been updated with changes to medical necessity criteria and medical coding requirements, effective immediately. The billing team must review updated coverage rules and coding guidelines to ensure compliant claim submission for this chemotherapy agent.
Action Required
By 2026-07-13: Billing team and oncology providers must access the full policy text at https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=07&FilterField2=MPSiteActivityLogYear&FilterValue2=2026#commercial-08-00-90v to review specific changes to medical necessity criteria and coding requirements for Abraxane claims. Update billing software, encounter documentation templates, and prior authorization workflows to reflect new criteria. Ensure all staff who process oncology pharmacy claims are trained on updated requirements. Failure to comply with new medical necessity criteria may result in claim denials or recoupments.